# Harvard-wide Program on Antibiotic Resistance

> **NIH NIH P01** · MASSACHUSETTS EYE AND EAR INFIRMARY · 2022 · $2,362,774

## Abstract

SUMMARY
The goal of the Harvard-wide Program on Antibiotic Resistance is to apply innovative advanced
technologies to developing new strategies for treating leading causes of multidrug resistant
hospital-associated infection caused by staphylococci and enterococci. Although much attention
has appropriately been focused on the recent emergence of pan-resistant gram negative bacteria,
staphylococci and enterococci remain the leading causes of both morbidity and mortality
associated with infection by multidrug resistant ESKAPE pathogens, highlighting the limitation of
current therapeutic approaches. This multi-investigator project brings together experts from fields
ranging from mathematics and systems biology to infectious disease clinicians, and creates an
infrastructure for them to work collaboratively and synergistically, bringing new insights and
capabilities to bear in solving the leading public health crisis of antibiotic resistant infection.
Important discoveries and advances were made in the previous period of support by pressing the
envelope with new technologies, including the most advanced high throughput mutational and
comparative genomic analyses yet conducted on these microbes. In the proposed continuation
period, these technologies will be combined with the latest advances in microfluidics and single
cell time lapse imaging, to reveal new vulnerabilities of these bacteria for targeting by new
compounds. The development and use of innovative screens that de-risk targets as well as unveil
new opportunities, inform the design of new and more efficacious compounds for treating
multidrug resistant staphylococcal and enterococcal infection. Filling critical knowledge gaps
related to the various mechanisms by which microbes survive antibiotic challenge, including
stochastic entry into alternate growth states and actively reducing drug concentration through
efflux, make this program exceptionally comprehensive in its approach. Finally, this project
actively shares its results with the community by establishing and promoting information exchange
and networking with other academic and industry scientists, and by ensuring important antibiotic
discovery knowledge is preserved and transmitted to the next generation of scientists. As a result
of internal and external synergies, the impact of the Harvard-wide Program on Antibiotic
Resistance is much greater than would otherwise be possible through individual research efforts.

## Key facts

- **NIH application ID:** 10327899
- **Project number:** 2P01AI083214-14
- **Recipient organization:** MASSACHUSETTS EYE AND EAR INFIRMARY
- **Principal Investigator:** Michael S Gilmore
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,362,774
- **Award type:** 2
- **Project period:** 2009-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10327899

## Citation

> US National Institutes of Health, RePORTER application 10327899, Harvard-wide Program on Antibiotic Resistance (2P01AI083214-14). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10327899. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*